An observational study in Atrial Fibrillation, sponsored by Volta Medical. Recruiting at 13 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-13.
Sponsored by Volta Medical · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 317 studies in Atrial Fibrillation with a site in France — 63 open to participants now, 87 under way, 5 of them phase 3. Atrial Fibrillation · France.
Among the 317 studies in Atrial Fibrillation with a site in France, this one is the 60th largest by planned enrollment of the 123 observational ones that give a count, is one of 11 that started in 2025, is one of 124 observational ones, reaches primary completion later than 54 of the 86 other live ones, and was the 291st registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →63 of the 317 studies in Atrial Fibrillation with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Universitaire Dijon · Sites in France
Ages 18+
Poitiers University Hospital · Sites in France
Ages 18–90
Volta Medical · Sites in France
Ages 18+
Oslo University Hospital · Sites in France, United States, Belgium and 7 more countries
Ages 18+
Boston Scientific Corporation · Sites in France, Belgium, Croatia and 2 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
317 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 12 · Phase 3 42 · Phase 4 24
First in 1999; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 278 is close to the median of 300 across 1,405 observational studies indexed under Atrial Fibrillation.
Median enrollment 250 across the 193 interventional studies, 250 across the 123 observational. Of the 205 that completed or were terminated, 61 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
134 of 317 have an industry lead sponsor. The 10 most frequent:
Volta Medical is the lead sponsor of 8 studies on the registry; 4 are open to participants now.
Volta Medical has 8 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
23 of the studies in Atrial Fibrillation with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT05773638University Hospital, BrestCardiovascular and Venous Thromboembolism Disease in Patients with Von Willebrand Disease in the French West | 2026-12-26 |
| NCT05777551Clinica MediterraneaAF Ablation With High Power Short Duration RF | 2026-12-31 |
| NCT05790707Poitiers University HospitalEfFect of Ablation of Persistent AtriaL Fibrillation on COgNitive Function in Individuals With Mild Cognitive Impairment | 2027-01 |
| NCT07116525Biosense Webster, Inc.A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter | 2027-02-07 |
Add all 23 to your calendar (.ics) → With an account.
Among the 317 studies in Atrial Fibrillation with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The TAILORED-LT study is conducted as an extension follow-up until 5 years of the initial TAILORED-AF study (NCT04702451), in order to demonstrate the long-term superiority in terms of freedom of atrial fibrillation (AF) of a tailored ablation strategy targeting areas of spatio-temporal dispersed electrograms in combination with pulmonary veins isolation (PVI) over an anatomical ablation strategy targeting PVI alone for the initial ablation procedure of persistent AF.
The TAILORED-AF study demonstrated at one year's follow-up that a tailored ablation strategy guided by Volta Medical AI-software targeting areas of spatio-temporal dispersed electrograms in combination with pulmonary vein isolation (PVI) ablation is more effective to an anatomical ablation strategy targeting PVI alone (current standard of care) for the treatment of persistent atrial fibrillation (AF).
VX1 legacy device renamed Volta AF-Xplorer was used in the TAILORED-AF study in the treatment arm.
No additional treatments are specifically required in the scope of this ancillary TAILORED-LT study which aims to follow the patients previously treated in the initial TAILORED-AF study over the long-term. However, in the event of repeat procedures during the TAILORED-LT study, the choice of the ablation technique will be left to the investigator's discretion, regardless of the patient's randomization arm in the TAILORED-AF study.
The annual follow-up will be performed as in routine clinical practice post AF ablation procedures: visits at 24 months, 36 months, 48 months and 60 months post TAILORED-AF Study index procedure. It is possible that some of these annual visits cannot be completed prospectively due to time already having elapsed between the end of the subject participation in the TAILORED-AF study and the date of enrollment in the extension TAILORED-LT study. In this case, available data (among those expected by the study protocol) will be collected retrospectively.
The additional procedures related to this clinical investigation are limited to annual 24-hour Holters and to the administration of Quality Of Life questionnaires (SF-36 and AFEQT) to the patients during follow-up visits.
Patients previously enrolled in TAILORED-AF study, treated for their persistent AF by an index ablation procedure and not withdrawn during the 12-month follow-up period post-index procedure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients from the "Tailored" group in the initial study TAILORED-AF. Patients in this group underwent "Tailored" AF ablation, i.e. the analysis and targeting of pathological areas using Volta Medical's artificial intelligence software (Volta AF-Xplorer, formerly VX1), in addition to electrical isolation of the pulmonary veins (PVI).
Device: Volta AF-Xplorer · Procedure: Dispersion ablation + PVI
Patients from the "Anatomical" group in the initial study TAILORED-AF. Patients in this group underwent PVI only.
Procedure: PVI
Dispersion ablation strategy guided by Volta Medical AI-software targeting areas of spatiotemporal dispersed electrograms
TAILORED-AF index procedure: Dispersion ablation + PVI
TAILORED-AF index procedure: PVI only
Long-term freedom from documented atrial fibrillation (AF) after one ablation procedure
Long-term freedom from documented AF episodes \> 30 seconds, with or without antiarrhythmic drugs (AADs), after a single index ablation procedure.
Time frame: 60 months
Long-term freedom from documented AF/AT after one or two ablation procedures
Long-term freedom from documented AF and Atrial Tachycardia (AT) episodes \> 30 seconds, after one or two procedures, with or without AADs
Time frame: 60 months
Long-term freedom from documented AF/AT after one ablation procedure
Long-term freedom from documented AF/AT episodes \> 30 seconds, after one procedure, with or without AADs
Time frame: 60 months
Heath Economics - Average Number of Ablation Procedures per patient
To determine how the number of repeat ablation procedures in addition to the index procedure impacts health care costs.
Time frame: 60 months
Heath Economics - Average Number of Hospitalizations per patient
To determine how the number of hospitalizations post-ablation index procedure impacts health care costs.
Time frame: 60 months
Heath Economics - Average Number of Cardioversions per patient
To determine how the number of cardioversions post-ablation index procedure affects health care costs.
Time frame: 60 months
Heath Economics - Quality of Life Progression (AFEQT Score)
To determine how the quality of life progression after the ablation index procedure (measured with the Atrial Fibrillation Effect on Quality of Life Questionnaire AFEQT) impacts health care costs. AFEQT score ranges from 0 to 100, with higher scores indicating better quality of life.
Time frame: 60 months
Heath Economics - Quality of Life Progression (SF-36 Score)
To determine how the Quality of life progression after the ablation index procedure (measured with the 36-Item Short Form Health Survey SF-36) impacts health care costs. The SF-36 consists of eight domains measuring physical and mental health, with scores ranging from 0 to 100 (higher scores indicate better quality of life).
Time frame: 60 months
Heath Economics - Proportion of Patients Under AAD
To determine how the proportion of patients under antiarrhythmic drugs (AAD) impacts health care costs.
Time frame: 60 months
Incidence of complications (safety composite endpoint)
Incidence of complications: death, cerebrovascular events, or serious treatment-related adverse event at long-term. NOTE: In addition, each component of the composite endpoint will be individually assessed.
Time frame: 60 months
Plan to share: No
Started Mar 2025 (actual). Primary completion is estimated for Dec 2027, 33 months after the start.
Of 148 industry-sponsored observational studies under Atrial Fibrillation, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 42. This study's planned 33 months is above that.
Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Volta Medical